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TP53 mutation is an independent marker
of poor prognosis in patients with diffuse
large B-cell lymphoma (DLBCL) treated
with cyclophosphamide, hydroxydauno-
rubicin, vincristine, and prednisone
(CHOP) therapy. However, its prognostic
value in the rituximab immunochemo-
therapy era remains undefined. In the
present study of a large cohort of DLBCL
patients treated with rituximab plus CHOP
(R-CHOP), we show that those with TP53
mutations had worse overall and
progression-free survival compared with
those without. Unlike earlier studies of
patients treated with CHOP, TP53 muta-
tion has predictive value for R-CHOP–
treated patients with either the germinal
center B-cell or activated B-cell DLBCL
subtypes. Furthermore, we identified the
loop-sheet-helix and L3 motifs in the DNA-
binding domain to be the most critical
structures for maintaining p53 function.
In contrast, TP53 deletion and loss of
heterozygosity did not confer worse sur-
vival. If gene mutation data are not avail-
able, immunohistochemical analysis
showing > 50% cells expressing p53 pro-
tein is a useful surrogate and was able to
stratify patients with significantly differ-
ent prognoses. We conclude that assess-
ment of TP53 mutation status is impor-
tant for stratifying R-CHOP–treated
patients into distinct prognostic subsets
and has significant value in the design of
future therapeutic strategies. (Blood.
2012;120(19):3986-3996)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
(30%-40%) and perhaps the most heterogeneous type of non-
Hodgkin lymphoma and has aggressive clinical features. Using
gene-expression profiling (GEP), DLBCLs can be classified into
2 molecularly distinctive types: germinal center B-cell like
(GCB) and activated B-cell like (ABC) that resemble the GEPs
of normal germinal center B cells and mitogenically activated
blood B cells, respectively.1 Despite this heterogeneity, DLBCL
patients are usually treated with the same combination chemo-
therapy regimen, traditionally cyclophosphamide, hydroxydauno-
rubicin, vincristine, and prednisone (CHOP), and in the past
decade, rituximab plus CHOP (R-CHOP). R-CHOP has clearly
improved the outcome of DLBCL patients. In a study of young
patients, the 6-year event-free survival (EFS) was shown to be
74.3% and overall survival (OS) was 94.9%.2 In elderly patients,
the rate of complete response (CR) has been shown to be 76%3;
the 10-year progression-free survival (PFS) was shown to be
36.5% and the OS 43.5%.4 However, among patients with re-
fractory disease or with early relapse, the CR rate was only 38%,
and the 3-year EFS rate was only 31% after high-dose chemo-
therapy and autologous stem-cell transplantation.5 Therefore,
the identification of prognostic biomarkers for high-risk DLBCL
subgroups is essential for designing targeted chemotherapy.
The p53 (TP53) protein (393 aa) encoded by the TP53 gene is
a crucial tumor suppressor that mediates cell-cycle arrest, DNA re-
pair, apoptosis, senescence, and autophagy under cellular stress via
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transcription-dependent activity (TA) and transcription-independent
activity (TIA) in the nucleus and cytoplasm, respectively.6,7 TP53
dysfunction is implicated in lymphomagenesis and disease progres-
sion,8,9 and normal function of TA and TIA of p53 is crucial for
tumor suppression.10,11 Nonsynonymous TP53 mutations alter the
p53 protein sequence and structure, disrupt function, and in many
tumors are the most common mechanism that inactivates TP53.
TP53 mutations could provide prognostic and predictive informa-
tion to guide more targeted therapy for lymphoma patients.12
The DNA-binding domain (DBD) of p53 is the most
important domain for its TA and TIA,13,14 so most TP53
mutations occur in the DBD encoded by exons 4-8 of the TP53
gene.15,16 In our previous study of TP53 mutations in 477 DL-
BCL patients treated with CHOP therapy,17 we detected exon
5-9 TP53 mutations in 21.4% of DLBCL patients, 66% of which
occurred in the loop (L1)–sheet-helix (LSH) motif and 2 large
loops L2 and L3, which are crucial for DNA binding.18,19
Functionally, TA of most p53 mutants have been characterized
by a yeast-based functional assay20 and in some human and
yeast lines, available in the International Agency for Research in
Cancer (IARC) TP53 database (http://www.iarc.fr).15 Many p53
mutants (MUT-TP53) exhibit dominant-negative characteristics
on wild-type p53 (WT-TP53) function by associating together as
tetramers.
The prognostic significance of TP53 mutations has been
inconsistent in several cancers, probably because of limitations
of mutation detection methods, heterogeneity of TP53 muta-
tions, inherent heterogeneity of disease, different therapies,
diversity of p53 functions, and other mechanisms that inactivate
the TP53 pathway.13,21,22 Our study and others have shown that
TP53 mutation is an independent prognostic indicator of
poor survival in DLBCL patients treated with CHOP
chemotherapy.16,17,23-25 In our earlier study using a different
DLBCL patient cohort treated with CHOP therapy, TP53
mutations were correlated with worse OS, mostly attributable to
the poor prognostic impact of TP53 mutations in the DBD.
When we subgrouped patients into GCB- and non–GCB-
DLBCL based on GEP data, the predictive value of TP53
mutations was restricted to patients with GCB-DLBCL.17
The anti-CD20 Ab rituximab combined with CHOP has
significantly improved survival of DLBCL patients. Rituximab
acts through 3 mechanisms: direct signaling, complement-
mediated cytotoxicity, and Ab-dependent cellular cytotoxicity.26
Influx of external calcium (Ca2) is essential for signaling-
induced apoptosis mediated by the BCR and CD20.27,28 Thera-
peutic (high) doses of rituximab induce intracellular Ca2
mobilization independently of CD20 and inhibit tumor cell
growth.29 The effects of rituximab are attributed to inhibition of
the BCR-signaling cascade,30 p38, NF-B, ERK, and Akt and
down-regulation of cytokine IL-10 and BCL-2.26 The TA and
function of p53 might differ after rituximab addition as a result
of different stresses induced by R-CHOP and CHOP because the
p53 transcriptional program is stimulus and cell-type spe-
cific.13,31 The TIA of p53 can also be affected by the p53-
independent signaling pathways induced by rituximab. There-
fore, the prognostic value of TP53 mutation in DLBCL patients
treated with R-CHOP needs to be evaluated.
To address the prognostic significance of TP53 mutations in
DLBCL, in the present study, we analyzed exons 2-11 of TP53 in a
large cohort of de novo DLBCL patients treated with R-CHOP and
compared mutation status with clinical outcome.
Methods
Patients
The study cohort consisted of 506 de novo DLBCL patients treated with
R-CHOP therapy in 29 medical centers selected based on the eligibility and
exclusion criteria of histology, treatments, availability of clinical data, and
biologic results. All patients were diagnosed according to the World Health
Organization (WHO) criteria and reviewed by a group of hematopatholo-
gists (participating center pathologists were S.M.-M., M.A.P., M.B.M.,
A.T., and K.H.Y.). Patients with primary mediastinal large B-cell lym-
phoma, cutaneous or CNS DLBCL, HIV infection, or a history of low-grade
B-cell lymphoma with transformation to DLBCL were excluded.32,33
Eligible patients were diagnosed between June 15, 1998 and October 8,
2008 (14 patients diagnosed in 1998-1999 were enrolled in the R-CHOP
clinical trials). Most patients (n  416) underwent 6-8 cycles of R-CHOP-
21; others (n  90) received R-CHOP–like regimens. In 182 patients,
radiotherapy (25-50 Gy) followed R-CHOP and in 29 patients, hematopoi-
etic stem cell transplantation followed R-CHOP (7 patients received both
radiotherapy and transplantation). Treatment responses (CR, partial re-
sponse, stable disease, and progressive disease) and follow-up were
evaluated according to the recommended criteria.34,35 Thirty-eight percent
(193 of 506) of the patients had died by the last follow-up. The median
follow-up interval for the 313 censored patients was 59.73 months (range,
12-180.26). The present study, conducted in accordance with the Declara-
tion of Helsinki, was approved as being of minimal or no risk or as exempt
by the institutional review boards of all participating centers, and the overall
study was approved by the institutional review board of the University of
Texas MD Anderson Cancer Center.
TP53 mutations by resequencing microarray
Genomic DNAs extracted from formalin-fixed, paraffin-embedded (FFPE)
tissues were used for TP53 exon sequencing. Sequencing of the coding
sequence (exons 2-11) and splicing sites was performed using p53
AmpliChip (Roche Molecular Systems).36 For data analysis and classifica-
tion, TP53 sequences were generated and compared with the TP53
reference sequence (NC_000017.10) in the GenBank database.
GEP and subtype classification
Total RNAs extracted from FFPE tissues were subjected to GEP using
Affymetrix GeneChip Human Genome HG-U133 Plus Version 2.0 to
classify 506 DLBCL patients into GCB or ABC subtypes, as described
previously.33 Immunohistochemistry (IHC) based on staining of biomarkers
including CD10, BCL-6, GCET-1, FOXP-1, and MUM-133 was performed
on tissue microarrays to classify the 506 patients according to the
Visco-Young algorithm with high concordance with GEP analysis, as
described previously.33
FISH for TP53 gene (chromosome 17p13.1) deletion
Among the 506 DLBCL patients studied by GEP, 440 FFPE tissue sections
were available for evaluation of chromosome 17p13.1 deletions by
interphase FISH using a LSI TP53 Spectrum Orange Probe (Vysis) and
methods described previously.16 A CEP 18 Spectrum Aqua Probe (Vysis)
was used to evaluate simultaneously for chromosome 17 copy number. The
ratio of TP53 signals (orange) to centromere 17 signals (green) was counted
in 200 tumor cells. A ratio lower than 0.81 was considered to support the
presence of a TP53 deletion. Because no patients had a ratio below 0.5, it
was assumed that no homozygous deletions occurred.
IHC for p53
IHC staining was performed for all patients using a method described
previously and the DO-7 mAb (DAKO).16 The percentage of positive tumor
TP53 MUTATIONS IN DLBCL PATIENTS TREATED WITH R-CHOP 3987BLOOD, 8 NOVEMBER 2012  VOLUME 120, NUMBER 19
For personal use only.on January 29, 2017. by guest  www.bloodjournal.orgFrom 
cells for each DLBCL patient in 5% increments was evaluated indepen-
dently by a group of 6 pathologists in addition to each contributing center
pathologist, and disagreements were resolved by joint review on a
multihead microscope. Receiver operating characteristic (ROC) curve
analysis was performed using Prism Version 5 software (GraphPad) to
assess the discriminatory accuracy of p53 protein overexpression in
predicting TP53 mutation status.
Statistical analysis
A comparison of clinical and laboratory features at the time of presentation
between different DLBCL subgroups was carried out using the 2 test and
the Spearman rank correlation. OS was calculated from time of diagnosis to
time of death from any cause. PFS was calculated from the time of
diagnosis to the time of progression or death from any cause.35 Patients who
remained alive or progression free were censored at the time of last
follow-up. Multivariate analysis for survival of the study cohort was
performed with SAS Version 9.3 software for Windows (SAS Institute)
using the Cox proportional hazards regression model. OS and PFS curves of
different groups were analyzed by Prism 5 using the Kaplan-Meier method
and differences were compared using the log-rank (Mantel-Cox) test. All
differences with P  .05 were considered to be statistically significant.
Results
Most TP53 mutations present in DLBCL are missense
mutations in the DBD
Gene sequencing detected 133 TP53 gene mutations in 112 DLBCL
patients, including 111 (21.9%) patients with nonsynonymous
mutations or p53 mutants (MUT-TP53) and 17 patients with
multiple (2-4) mutations. Mutation prevalence and patterns are
shown in Figure 1A-B and Table 1. The 112 patients with 133 TP53
mutations included 92 with missense mutations (including 15 pa-
tients who carried 2 missense mutations); 14 with a nonsense
mutation; 2 with a 2-bp deletion resulting in frameshift; 3 with a
silent mutation; and 7 carrying a mutation in splicing sites.
Missense mutations accounted for 81% of the total mutations
present in this cohort.
The exon and codon distributions of these mutations are shown
in Figure 1D and E. Exons 5-8 were most often mutated. A total of
117 (88.6%) mutations occurred in the DBD, including 25 (18.9%)
in L3, 24 (18.2%) in the LSH motif, and 20 (15.2%) in L2. Codons
248, 273, 175, 176, and 213 of the p53 protein had the highest
mutation frequency. Codons 248, 273, and 175 are the TP53
mutation hot spots found in most human cancers.
Most missense and nonsense mutations are loss-of-function
mutations
Functional analysis of TP53 mutations using bioinformatics
models. Functional prediction of the 121 missense or nonsense
mutations was computed by SIFT (http://sift.jcvi.org/) and AGVGD
(http://agvgd.iarc.fr/) methods based on protein sequence homol-
ogy. By SIFT, 108 (90%) missense or nonsense mutations were pre-
dicted to be deleterious (disrupt the p53 function), and 12 (10%)
missense or nonsense mutations were predicted to be tolerable
(neutral). By AGVGD, 99 (81.8%) missense mutations were
predicted to be deleterious and 8 (6.6%) missense mutations were
predicted to be neutral.
Yeast-based functional assay data in IARC database. Effect
of mutations on p53 transcription function can be retrieved from
Figure 1. Patterns of TP53 mutations in 506 DLBCL patients treated with R-CHOP. (A) Proportions of classified point mutations. (B) Proportions of mutations based on
mutation impact on the p53 protein sequence. (C) Proportions of mutations based on mutation effect on the p53 function. (D) Distribution of mutation numbers according to
TP53 exons. The numerals on top are numbers of mutations in exons, and the numerals at the bottom are numbers of mutations in splicing sites. (E) Codon distribution of TP53
mutations. Codons with mutations of high frequency in the cohort are marked.
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the International Agency for Research on Cancer (IARC) TP53
database (http://www.iarc.fr; TP53MutFunction2R15 dataset) that
was established by a p53 transactivation activity assay in 8 yeast
promoters (WAF1, MDM2, BAX, 14-3-3, p53AIP1, GADD45,
NOXA, and p53R2) that harbor p53 response elements. Of 133 de-
tected mutations, there were 99 mutation variants (some patients
carried the same TP53 mutation variant), including 79 missense
mutation variants, 9 nonsense mutations resulting in truncated
protein, 6 splicing mutation variants, 2 frameshift mutation variants
in exon 6 or 7, and 3 silent mutations. Among the 88 missense
and nonsense mutation variants, 66 (75%) were nonfunctional,
16 (18.2%) partially functional, and only 4 (4.5%) functional, as
experimentally measured by the yeast-based functional assay
(Figure 1C). These data correspond to 94 (77.7%) nonfunctional,
18 (15%) partially functional, and 5 (4%) functional mutations
among the 121 detected missense and nonsense mutations, with
4 missense or nonsense mutations uncharacterized. Splicing muta-
tions and frameshift mutations result in more alterations of protein
sequence than missense mutations and therefore potentially have
a more deleterious effect on p53 function. Altogether, more than
90% of mutations result in loss of p53 function. Most mutations at
hot spots, including R248W, R248Q, R273C, R273H, R175H,
C176R, R213X, and R213Q, are nonfunctional, whereas C176F is
partially functional, and R175C is functional. Furthermore, accord-
ing to the IARC TP53MutFunction1R15 dataset, 32 mutants
detected have a dominant-negative effect on p53 transcription
function, and 3 mutants have lost the ability to form tetramers.
Functional data for a limited number of missense and nonsense
mutants regarding TIA are available in the IARC TP53
MutFunction1R15 dataset. R175H, Y234C, G245S, R248Q,
R248W, R273H, C277Y (partial), R280K, and R337C (partial)
have lost the ability to induce apoptosis in human cells, whereas
S121F, R175C, R181C, and S240R are functional or partially
functional regarding transcriptional activities and have conserved
apoptosis function. Altogether, either by bioinformatic computa-
tions or by laboratory-based evaluation, approximately 90% of
TP53 mutations detected in this study cohort were accompanied by
a loss of p53 function.
Clinical features of the cohort
The clinical features of the WT-TP53 and MUT-TP53 groups are
compared and summarized in Table 2. There were no significant
differences between these 2 groups regarding age, sex, stage,
B symptoms, number of extranodal sites, performance status,
tumor size, or International Prognostic Index (IPI). Serum lactate
dehydrogenase level (P  .05), tumor size (P  .02), and therapeu-
tic response (P  .0001) were the only variables that were signifi-
cantly different between these 2 groups.
Most patients were able to be classified into GCB- and
ABC-DLBCL subtypes according to the GEP data (n  441),
supplemented by IHC assessment (n  499). Of these, 258 patients
were determined to be the GCB subtype, including 190 patients
with WT-TP53 and 68 patients with MUT-TP53; 241 patients were
determined to be the ABC subtype, including 198 patients with
WT-TP53 and 43 patients with MUT-TP53. Serum lactate dehydro-
genase (P  .005), tumor size (P  .013), and therapeutic response
(P  .0009) differed significantly in patients with WT-TP53 versus
MUT-TP53 in the GCB subtype, whereas only therapeutic response
differed significantly in patients with WT-TP53 versus MUT-TP53
(P  .0113) in the ABC subtype.
Impact of TP53 mutations on survival in DLBCL patients treated
with R-CHOP
TP53 mutations predict poor survival in all DLBCL patients.
Our results show that TP53 mutation status is a significant
prognostic factor that stratifies DLBCL patients treated with
R-CHOP. DLBCL patients with WT-TP53 had significantly better
OS and PFS compared with DLBCL with MUT-TP53 (P  .0005
and P  .0004, respectively; Figure 2A-B). The median OS of
395 patients with WT-TP53 DLBCL was 94.49 months, in contrast
to 52.90 months for 111 patients with MUT-TP53 (hazard ratio
[HR]  0.5320; 95% confidence interval [CI], 0.37-0.76). Patients
with MUT-TP53 were associated with a significantly higher,
1.9 times (95% CI, 1.32-2.68) hazard for OS (poorer survival)
compared with patients with WT-TP53. The 5-year OS was 65.9%
for patients with WT-TP53 versus 47.8% for those with MUT-TP53
DLBCL. The median PFS for patients with WT-TP53 DLBCL was
93.14 months versus 51.95 months for patients with MUT-TP53
DLBCL (HR  0.5370; 95% CI, 0.38-0.76). The 5-year PFS was
63.5% for DLBCL patients with WT-TP53 versus 46.3% with
MUT-TP53.
TP53 mutations predict poor survival in both the GCB- and
ABC-DLBCL subtypes. GCB-DLBCL patients had significantly
better survival than ABC-DLBCL patients (supplemental Figure
1A-B, available on the Blood Web site; see the Supplemental
Materials link at the top of the online article). GCB-DLBCL
patients with WT-TP53 had better OS (P  .0024; HR  0.46;
95% CI, 0.28-0.76) and PFS (P  .0013; HR  0.4483; 95% CI,
0.28-0.73) than GCB-DLBCL patients with MUT-TP53 (Figure
2C-D). Similarly, ABC-DLBCL patients with WT-TP53 had better
survival than ABC-DLBCL patients with MUT-TP53 (P  .0112,
HR  0.5218, and 95% CI, 0.32-0.86 for OS; P  .0259,
Table 1. Mutation prevalence in 506 de novo DLBCL patients treated with R-CHOP
No. of patients Prevalence No. of mutations No. of mutation variants
Total patients 506 133 99
Patients with WT-TP53* 395 78% 1 1
Patients with MUT-TP53† 111 22% 132 98
Patients with missense mutations‡ 92 18.2% 107 79
Patients with nonsense mutations 14 2.8% 14 9
Patients with a 2-bp deletion causing reading frame shift 2 0.4% 2 2
Patients with silent mutations§ 2 0.6% 2 2
Patients with a mutation at the splicing sites¶ 7 1.4% 7 6
*One DLBCL patient with only 1 silent mutation is also counted as WT-TP53.
†Seventeen DLBCL patients had multiple (2-4) mutations.
‡Fifteen DLBCL patients had 2 missense mutations.
§These 2 patients also carried missense mutations.
¶Four patients carrying a mutation at the splicing site also carried missense mutations.
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HR  0.5665, and 95% CI, 0.34-0.93 for PFS; Figure 2E-F).
Multivariate analysis. Multivariate analysis showed that an
IPI score of  2, TP53 mutation, ABC subtype, and B symptoms
were the only prognostic factors that independently predicted
worse OS and PFS in DLBCL patients treated with R-CHOP (Table
3). TP53 mutation is an important prognostic marker second to an
IPI score of  2. Patients with TP53 mutation had a 1.95 times
hazard for OS (P  .0004) and a 1.84 times hazard (P  .001) for
PFS compared with patients without TP53 mutation.
TP53 mutations in the LSH, L2, and L3 motifs predict poor
survival in DLBCL patients. Because most (105 of 111; 95%)
MUT-TP53 DLBCL patients carried mutations in the DBD,
survival curves for DLBCL patients with DBD TP53 mutations
versus those with WT-TP53 closely mirrored the overall MUT-
TP53 versus WT-TP53 data (figures not shown). Mutations in the
3 important motifs for DNA binding, LSH, L2, and L3, were all
significantly associated with worse survival (Figure 3A-F). Muta-
tions in LSH (including the codon 273 hot spot) and L3 (including
the codon 248 hot spot) were particularly associated with decreased
survival: for LSH, a median OS of 26.76 months and PFS of
27.64 months, and for L3, a median OS of 30.64 months and PFS of
23.23 months. The median OS and PFS for L2 mutations (52.90 and
48.99 months, respectively) were similar to those of DLBCL
patients with MUT-TP53 overall.
Differentially expressed genes in MUT-TP53 and WT-TP53
patients
To identify the genes responsible for the different clinical outcomes
of DLBCL patients with WT-TP53 versus MUT-TP53 and the
different therapeutic response in DLBCL patients with GCB versus
ABC subtypes, we profiled and compared the GEPs of WT-TP53
and MUT-TP53 DLBCLs (Figure 4A-B). Twenty probe sets were
significantly differentially expressed between WT-TP53 and MUT-
TP53 DLBCL patients. Genes up-regulated in WT-TP53 DLBCL
included: DOK7, DHRS9, HLA-DPB2, BATF3, RPS27L, and
DUSP2; genes down-regulated included: PEG10, CDKN2A,
CTAG1A/CTAG1B, TMEM97, NDC80, LOC96610, KIAA0020,
and DKC1.
The impact of p53 status on GEP was different in GCB- and
ABC-DLBCL. In GCB-DLBCL (Figure 4B), 40 probe sets were
differentially expressed between MUT-TP53 and WT-TP53.
Genes up-regulated in WT-TP53 included: HOPX, DHRS9,
LOC100510485, CACNA1D, BATF3, DNER, SOCS1, CAMTA1,
LOC729121, and MPP4; genes down-regulated included KIAA0101,
PEG10, TMEM97, GPR180, TAF4B, CDKN2A, FAM72A, FAM72B,
FAM72C, FAM72D, MCM4, E2F1, ATAD2, SLC16A1, NDC80,
FIGNL1, WDHD1, NCAPG2, DKC1, SQLE, NDUFA1, CDK4,
EIF4G1, DUS4L, TFAM, PA2G4, PA2G4P4, and APLP2. In
Table 2. Clinical characteristics of 506 de novo DLBCL with GCB or ABC subtypes treated with R-CHOP: comparison between patients with
or without TP53 mutations
Overall (N  506) GCB (n  258) ABC (n  241)
WT-TP53 MUT-TP53 P WT-TP53 MUT-TP53 P WT-TP53 MUT-TP53 P
Patients, n 395 111 190 68 198 43
Age
 60 y 163 43 94 33 64 10
 60 y 232 68 .2073 96 35 .8937 134 33 .2427
Sex
F 164 46 82 27 77 19
M 231 65 .9883 108 41 .6209 121 24 .5201
Stage
I-II 183 54 104 33 74 21
III-IV 192 57 .9776 72 35 .1361 118 22 .2137
B symptoms
No 232 66 119 41 108 25
Yes 112 29 .7073 44 20 .3929 67 9 .1900
LDH
Normal 129 27 71 14 57 13
Elevated 223 76 .0497 95 48 .0050 123 28 .9906
No. of extranodal sites
0-1 299 87 143 53 145 32
 2 75 21 .889 32 13 .8020 47 10 .9270
Performance status
0-1 289 89 133 55 149 34
 2 46 11 .4775 17 6 .7517 29 5 .5891
Size of largest tumor
 7.5 cm 241 60 114 38 124 22
 7.5 cm 63 29 .0201 27 21 .0130 34 8 .5349
IPI risk group
0-2 225 66 118 41 100 25
3-5 122 36 .9799 43 20 .3698 79 16 .5513
Therapy response*
CR 316 67  .0001 153 41 .0009 156 26 .0113
PR 45 23 19 14 26 9
SD 11 7 6 4 5 3
PD 23 14 12 9 11 5
LDH indicates lactate dehydrogenase; PR, partial response; SD, stable disease; and PD, progressive disease.
*For therapy response, we calculated P values as CR versus other responses.
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contrast, in ABC-DLBCL, only 1 gene (PSMD10) was significantly
down-regulated in the WT-TP53 compared with the MUT-TP53
patients. The functions and subcellular locations of these genes
(http://www.uniprot.org) are listed in supplemental Table 1.
Association of TP53 mutations and LOH
TP53 single-allele mutations are frequently followed by loss of
heterozygosity (LOH), further promoting tumor development and
disease progression.22,37 In the present study, we observed a weak
association between TP53 mutations detected by p53 AmpliChip
and TP53 deletions detected by FISH. Ninety-four MUT-TP53 and
346 WT-TP53 DLBCL patients were assessed by FISH (17 MUT-
TP53 and 49 WT-TP53 patients had no tissue available or FISH
failed). Overall, 12.3% of DLBCLs had allelic deletion, with a
lower frequency than mutation (21.9%). In the MUT-TP53 group,
there were 16 (17.0%) patients with TP53 allelic deletion. In
comparison, 38 (11.0%) patients in the WT-TP53 group had TP53
allelic deletion. Therefore, TP53 deletion (LOH) was more com-
mon in DLBCL with MUT-TP53; however, the frequency differ-
ence did not reach statistical significance (P  .1136). Conversely,
the TP53 mutation frequency was higher in DLBCLs with allelic
deletions (29.6%) than in tumors without deletions (20.5%), but
this was also not statistically significant (P  .1253). These results
suggest a weak association between allelic deletion and TP53
mutations.
Others have reported that complete inactivation of TP53 by
concomitant TP53 mutations and LOH is present most often in
high-grade lymphomas and might be associated with high-grade
transformation or disease progression.38 In the present DLBCL
study cohort, a significantly higher frequency (P  .025) of allelic
deletion was present in DLBCL patients with a high proliferation
index (Ki-67 protein 70%; high Ki-67  7.4% vs low Ki-
67  14.9%). TP53 mutations also occurred significantly more
frequently (P  .0235) in DLBCLs with a high Ki-67 index
(high  25.7% vs low  16.8%). In addition, 15 of 16 DLBCLs
with LOH concurrent with TP53 mutation had a high Ki-67 index.
These data suggest that TP53 mutations and LOH are associated
with a high Ki-67 index.
Impact of TP53 allelic deletion on patient survival. Our
results show that TP53 allelic deletion was not significantly
associated with decreased OS or PFS (Figure 5A-B). The impact of
allelic deletion might have been attenuated by the poor survival
potential of DLBCL patients with MUT-TP53 with or without
allelic deletion. Therefore, we further examined the impact of TP53
allelic deletion after stratifying patients into the WT-TP53 and
MUT-TP53 DLBCL subgroups. In DLBCL patients with either
WT-TP53 or MUT-TP53, allelic deletion was not correlated with
survival (Figure 5C-F.), although allelic deletion tended to be
correlated with decreased survival in DLBCL patients with
WT-TP53.
Because LOH and TP53 mutations are significantly associated
with high Ki-67, we assessed the impact of LOH and TP53
mutations on survival in patients with a high or low Ki-67 index.
Table 3. Multivariate analysis in terms of OS and PFS of patients
with DLBCL treated with R-CHOP
HR 95% CI P
OS
IPI  2 2.63 1.87-3.69  .0001
TP53 mutation 1.95 1.34-2.83 .0004
ABC subtype 1.62 1.15-2.28 .0062
B symptoms 1.43 1.02-2.01 .0374
PFS
IPI  2 2.45 1.77-3.39  .0001
TP53 mutation 1.84 1.28-2.65 .0010
ABC subtype 1.60 1.15-2.24 .0052
B symptoms 1.43 1.03-1.99 .0323
Figure 2. DLBCL patients with WT-TP53 have signifi-
cantly better OS and PFS compared with DLBCL
patients with MUT-TP53.
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TP53 mutations, but not allelic deletion, affected survival signifi-
cantly in DLBCL patients with highly proliferative tumors (Ki-
67  70%; Figure 6A-D).
p53 overexpression by IHC in tissue sections. The p53 protein
expression level was determined in 483 DLBCL patients using
IHC. Different cutoffs of positive cells yielded different sensitivity
and specificity by ROC analysis (supplemental Table 2). Cutoffs
between 10% and 60% stratified DLBCL patients into 2 groups
with significantly different OS and PFS (P  .05; supplemental
Table 2). However, p53 overexpression determined by IHC using
cutoffs of 10%-40% is less discriminative than TP53 mutation
status to stratify DLBCL patients into groups with different
survival. Although a 30% cutoff of p53 expression by IHC had the
biggest Youden index, a cutoff of 50% had a higher specificity,
highest HR, and best P value in patient stratification. Therefore, we
believe that  50% is the best p53 expression cutoff with which to
stratify DLBCL patients in diagnostic practice if sequencing of
TP53 is not available.
Figure 3. DLBCL patients with TP53 mutations in the
LSH, L2, and L3 motifs of the DNA binding domain
have significantly inferior OS and PFS compared
with DLBCL patients with WT-TP53.
Figure 4. Genes differentially expressed between DLBCL patients with MUT-TP53 and WT-TP53. (A) Fourteen genes significantly differentially expressed in
DLBCL patients treated with R-CHOP. (B) Thirty-four genes significantly differentially expressed in the GCB-DLBCL subgroup.
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Discussion
In the present study, we found a TP53 mutation prevalence of
21.9% in DLBCL patients, and the mutation patterns were similar
to patterns in some other cancers. Most TP53 mutations were
missense mutations, suggesting the importance of maintaining p53
structure in tumor suppression. In addition, most mutations oc-
curred in the DBD, with hot spots at codons 248 (in L3), 273 (in
LSH), and 175 and 176 (in L2), indicating that these motifs are
critical for p53 tumor-suppression function. Bioinformatics tools
based on alignments of TP53 sequences during evolution predicted
that 90% of these missense mutations disrupt p53 function.
Functional assays in human or yeast cells confirmed that most of
these mutants lose transcriptional function. Impairment of
transcription-independent apoptosis function by TP53 mutations
has also been reported previously.39-41 The mutants R273H, L194F,
R175H, and E285K have a low ability to translocate to mitochon-
dria and induce apoptosis under stress conditions42; therefore, loss
of p53 TA or TIA could be a driver for lymphomagenesis.
In this large cohort of de novo DLBCL patients treated with
R-CHOP, we show that TP53 mutations, especially mutations in
the L3 and LSH motifs, are correlated with disease progression and
poor survival (Figures 2 and 3). To eliminate the possible impact of
radiotherapy and transplantation on survival, we also performed
survival analysis for patients who received standard R-CHOP
Figure 5. Impact of TP53 allelic deletion on OS and
PFS in DLBCL patients treated with R-CHOP, with
WT-TP53 or MUT-TP53.
Figure 6. TP53 mutations and allelic deletions demon-
strate distinct impacts on OS in DLBCL patients with
a low or high proliferation index. (A-B) TP53 allelic
deletions were not correlated with significantly inferior OS
in DLBCL patients with low or high proliferation index.
(C-D) TP53 mutations were correlated with significantly
inferior OS in DLBCL patients with high proliferation
index, but not in patients with low proliferation index.
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therapy only and found that patients with WT-TP53 had signifi-
cantly better OS (P  .0041) and PFS (P  .0084). Therefore,
despite the addition of rituximab to CHOP, TP53 mutation is an
independent prognostic factor that predicts poor survival in patients
with DLBCL. This observation holds true in patients with the GCB
or ABC subtypes of DLBCL (Figure 2C-F) and further supports the
crucial role of p53 in death of tumor cells and tumor suppression.
Nonetheless, the impact of TP53 mutation on survival of GCB-
DLBCL patients is more pronounced than for ABC-DLBCL
patients (Figure 2C-F). In fact, TP53 mutation status was not an
independent prognostic factor in patients with ABC-DLBCL
treated with CHOP.17 The distinctive molecular programs harbored
by GCB- and ABC-DLBCL43 might explain the differences in
treatment response and impact of TP53 mutations. Perhaps somatic
hypermutation (SHM) in GCB-DLBCL under chemotherapy may
trigger rapid apoptosis in WT-TP53 patients, whereas accumulation
of more oncogenic events in MUT-TP53 makes these tumors
resistant to apoptosis. In contrast, the SHM machinery is inacti-
vated in ABC-DLBCL, which instead expresses a pre-plasma cell
program. NF-B and BCR signaling pathways are activated in
ABC-DLBCL,43,44 causing resistance to apoptosis and chemo-
therapy, negatively affecting the survival of ABC-DLBCL patients
with WT-TP53, and minimizing the prognostic value of MUT-
TP53. Therefore, with CHOP treatment, TP53 status is an indepen-
dent predictor of treatment response only in the GCB subtype.
However, with R-CHOP therapy, rituximab inhibits the NF-B and
BCR signaling pathways, and ABC-DLBCL patients with MUT-
TP53 have significantly worse survival than those with WT-TP53.
In addition, similar to CHOP regimen, ABC-DLBCL patients
treated with R-CHOP have significantly inferior OS and PFS
compared with GCB-DLBCL patients both in the entire DLBCL
cohort (supplemental Figure 1A-B) and in the WT-TP53 subcohort
(supplemental Figure 1C-D). Our multivariate analysis also sug-
gested that ABC subtype independently predicted worse survival
(Table 3). These data are in agreement with a recent study.45 Most
of the clinical characteristics contributing to IPI score and IPI score
itself were significantly different between GCB-DLBCL and
ABC-DLBCL patients (supplemental Table 3) in overall DLBCL
and DLBCL with WT-TP53, suggesting that molecularly distinc-
tive types can be clinically reflected on IPI parameters. In DLBCL
patients with MUT-TP53, IPI score was not significantly different
between the GCB and ABC subtypes (supplemental Table 3);
correspondingly, OS and PFS were not significantly different
(supplemental Figure 1E-F). This might be because of the small
cohort of DLBCL patients with MUT-TP53, but also might reflect
the dominant adverse impact of p53 mutations on survival in both
the GCB and ABC subtypes.
We also performed GEP in DLBCL patients with WT-TP53 and
MUT-TP53, as well as according to GCB- and ABC-DLBCL
subtypes (Figure 4). One critical feature between WT-TP53 and
MUT-TP53 DLBCLs is that certain genes were differentially
expressed in GCB-DLBCL, but only 1 gene (PSMD10, a negative
regulator of RB1 and p53) was significantly down-regulated in
ABC-DLBCL with WT-TP53. These results imply either absence
or heterogeneity of the p53 transcription activities in ABC-DLBCL
and probably indicate that p53 is less activated in ABC- compared
with GCB-DLBCL, perhaps because of decreased activity of SHM.
Similar phenomena were observed previously in DLBCL patients
treated with CHOP.16,17 However, ABC-DLBCL patients with
WT-TP53 still had better survival compared with patients with
MUT-TP53 (Figure 2E-F), suggesting that transcription-independent
p53 function is mainly responsible for the better survival of
ABC-DLBCL patients with WT-TP53 treated with R-CHOP.
The GEP differences between WT-TP53 and MUT-TP53 DLB-
CLs (Figure 4) could be explained as loss or altered p53 function in
MUT-TP53. From this perspective, loss of tumor-suppressor func-
tion of MUT-TP53 includes transactivation of several genes
involved in signaling and transcription, including negative regula-
tors of ERK, JNK, and cytokine signaling pathways; activators of
the NOTCH1 pathway; and transrepression of several genes
involved in antiapoptosis, cell-cycle progression, biosynthesis,
proliferation, transcriptional activation, and G-protein signaling.
Conversely, the difference in gene expression between the WT-
TP53 and MUT-TP53 DLBCL patients may result from gain-of-
function of some MUT-TP53 mutants. The tumor-suppressor gene
CDKN2A (encoding p16INK4A and p14ARF) was down-regulated in
WT-TP53 DLBCL patients (Figure 4A-B). p16INK4A can cause
cell-cycle arrest by inhibiting CDK4; p14ARF sequesters the p53-
negative regulator MDM2, thereby enhancing p53 level and
activity, or induces cell-cycle arrest and apoptosis by p53-
independent pathways. p14ARF also inhibits the function of BCL-
6,46 which is expressed in B-cell germinal centers and activated in a
subset of lymphomas.44 The repression of CDKN2A by p53 has also
been reported in a cell line study,47 and might provide negative
feedback to the TP53 pathway.48 The known p53 targets (eg, MDM2,
BAX, and p21) did not appear to be differentially expressed
(P  insignificant), reflecting the biologic heterogeneity of
DLBCLs.
The prognostic value of p53 overexpression as a surrogate for
TP53 mutations has been studied by others, but with inconsistent
results. We used an IHC method to detect p53 overexpression and
compared it with TP53 mutation status. We evaluated different
cutoffs of p53 expression by ROC analysis and found that most
cutoffs were able to stratify patients with significantly different OS
and PFS. However, most stratification using IHC appears to be less
discriminating than TP53 mutation status. In the present study,
a  50% cutoff was determined to be the best for diagnostic
practice if gene-sequencing data are not available.
In contrast to TP53 mutations, we found that TP53 allelic
deletion, which also may inactivate the TP53 pathway, had no
significant impact on patient survival, either overall or within the
WT-TP53 or MUT-TP53 subsets (Figure 5C-F). In fact, DLBCL
patients with both LOH and MUT-TP53 had a slightly better
survival than DLBCL patients with MUT-TP53 alone (Figure
5E-F). The higher frequency of TP53 mutations than allelic
deletions in our cohort may imply that LOH occurred after TP53
mutation, which drives lymphomagenesis. LOH seemingly added
no further selective growth advantage for tumor cells that carried
TP53 mutation (Figure 5E-F), which probably reflects the dominant-
negative effect exerted by MUT-TP53 on WT-TP53 expressed from
the other intact allele and gain-of-function by MUT-TP53 resulting
in a greater decrease in survival than loss-of-function by LOH.
Alternatively, the slightly worse survival of MUT-TP53 patients
(Figure 5E-F) could be caused by TP53 mutations present in the
other allele. The AmpliChip we used for mutation detection cannot
distinguish between homozygous and heterozygous mutations, but
13 of 78 MUT-TP53 patients without LOH carried 2 or 3 different
TP53 mutations. The comparably weaker growth advantage pro-
vided by LOH compared with TP53 mutation explains the low
percentage of allelic deletions (17%) in MUT-TP53 DLBCLs and
also the absence of statistically significant association between
TP53 mutations and LOH in this cohort. However, concomitant
LOH and TP53 mutation were almost always in patients with a
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high proliferation index (Ki-67 70%), suggesting an association
of LOH with disease progression. Nonetheless, our results (Figure
6A-D) suggest that TP53 mutations and not LOH drive disease
progression.
In conclusion, in the present study, we identified TP53 mutation
patterns in a large cohort of patients with de novo DLBCL who
were treated with R-CHOP and confirmed that TP53 mutation
status is a valuable prognostic biomarker. TP53 mutations, espe-
cially the ones in the LSH, L3, and L2 motifs of the DBD, were
significantly correlated with worse survival in patients with either
GCB- or ABC-DLBCL. Therefore, therapeutic approaches target-
ing the inactivated TP53 pathway may further improve clinical
outcomes of patients with DLBCL treated with R-CHOP.49,50
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